Ionis Pharmaceuticals, Inc. (IONS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Neurocrine Biosciences, Inc.

Exelixis, Inc.

Jazz Pharmaceuticals Plc

Viatris, Inc.

Royalty Pharma Plc

United Therapeutics Corp.

Repligen Corp.

Sarepta Therapeutics, Inc.

Catalent, Inc.

Ionis Pharmaceuticals, Inc.

Roivant Sciences Ltd.

Why is Ionis Pharmaceuticals, Inc. ?

Poor Management Efficiency with a low ROE of 0.04%

The company has been able to generate a Return on Equity (avg) of 0.04% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate -173.66% of over the last 5 years

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at USD -910.63 MM
NET PROFIT(HY) At USD -344.9 MM has Grown at -40.09%
DEBT-EQUITY RATIO (HY) Highest at 128.73 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 102.88%, its profits have risen by 13.2%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ionis Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Ionis Pharmaceuticals, Inc.

102.88%

1.84

47.46%

S&P 500

22.99%

1.78

12.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.29%

EBIT Growth (5y)

-173.66%

EBIT to Interest (avg)

-6.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.73

Sales to Capital Employed (avg)

0.35

Tax Ratio

1.39%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

0.04%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

24.37

EV to EBIT

-30.33

EV to EBITDA

-32.25

EV to Capital Employed

70.86

EV to Sales

12.29

PEG Ratio

Dividend Yield

ROCE (Latest)

-233.64%

ROE (Latest)

-79.99%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -1.03% (YoY

CASH AND EQV(HY)

Highest at USD 4,654.5 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 4.05 times

-10What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -910.63 MM

NET PROFIT(HY)

At USD -344.9 MM has Grown at -40.09%

DEBT-EQUITY RATIO (HY)

Highest at 128.73 %

Here's what is working for Ionis Pharmaceuticals, Inc.

Cash and Eqv

Highest at USD 4,654.5 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 4.05 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -1.03% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 7.45 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Ionis Pharmaceuticals, Inc.

Net Profit

At USD -344.9 MM has Grown at -40.09%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -910.63 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Highest at 128.73 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio